04.07.25 -- Questions You And Your New CDMO Might Be Asking

For complex projects involving oral solid dosage (OSD) and sterile drug products, selecting the ideal CDMO can play a pivotal role in determining the success of a drug candidate.

Accelerating the development of adoptive cell therapies through robust preclinical strategies and regulatory pathways is crucial to bringing these life-saving treatments to patients in need.

Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of CGT development and production.

Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Service expectations for life science customers have evolved. Discover a solution that offers a comprehensive partnership, which provides proactive maintenance, expert guidance, and continuous support.

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

Optimize your mRNA production with an advanced IVT process, enhancing scalability, purity, and expression activity for clinically relevant RNA therapeutics.

Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success.

This HEK293-derived, animal component-free suspension cell line forms the foundation of a scalable, robust platform process that accelerates AAV manufacturing.